Shareholders to Vote on Massive Dilution from Class J Warrants

summarizeSummary

Revelation Biosciences is seeking shareholder approval for the potential issuance of common stock from Class J Warrants that could result in over 160% dilution, necessary for Nasdaq compliance following a recent $7.3 million capital raise.

check_boxKey Events

• Special Shareholder Meeting Scheduled

  A special meeting of stockholders will be held virtually on March 18, 2026, to vote on key proposals related to the company's capital structure.

• Vote on Significant Warrant Issuance

  Shareholders are asked to approve the reservation and issuance of common stock from Class J Warrants, which could exceed 20% of outstanding shares and trigger the Nasdaq Exchange Cap.

• Massive Potential Dilution

  The Class J Warrants represent 4.27 million shares, compared to 2.62 million outstanding shares (post-reverse split), indicating a potential dilution of over 160%.

• Follows Recent Capital Raise

  These warrants were issued as part of a warrant inducement on January 23, 2026, which successfully raised approximately $7.3 million to fund clinical development programs.

auto_awesomeAnalysis

Revelation Biosciences has filed a definitive proxy statement for a special shareholder meeting on March 18, 2026. The primary proposal seeks shareholder approval to issue common stock underlying Class J Warrants, specifically to exceed the 20% share issuance cap under Nasdaq rules. These warrants, representing 4.27 million shares, were issued as part of a January 23, 2026 warrant inducement that raised $7.3 million. With 2.62 million shares outstanding (post-reverse split), the potential issuance from these warrants represents over 160% dilution, which the company acknowledges as 'significant.' While the capital raise itself was crucial for funding clinical trials, the need for shareholder approval to exceed the Nasdaq cap highlights the substantial dilutive impact on existing shareholders. Approval is necessary for the company to remain compliant with Nasdaq listing rules and avoid mandatory shareholder meetings every 60 days.